Considering the fact that elevated levels of lipoprotein(a) or hyperlipoproteinemia(a) represent an independent causal risk factor for CVD strongly influenced by genetics, it is crucial to explore pharmacological approaches for to reduce Lp(a). This evidence concerns the gene LPA and hyperlipoproteinemia.